Hopkinton-based Lykan Bioscience, which is expanding its cell therapy manufacturing facility/laboratory on South Street, announced earlier this month that it has entered into a business agreement with Scotland-based RoslinCT to form a global-leading innovative advanced therapies contract development and manufacturing organization.

With demand for high-quality development and manufacturing capacity increasing across the world, this complementary pairing of RoslinCT and Lykan will shorten development and manufacturing timelines for advanced therapy sponsors, facilitating clinical and commercial good manufacturing practice (GMP) product release on both sides of the Atlantic, the company announced.

“We are delighted to combine with RoslinCT to better serve the growing demand for manufacturing capacity and expand the range of innovative services we can provide our partners to support the development of advanced cell and gene therapies,” stated Lykan President and Chief Executive Officer Patrick Lucy.

Lykan, founded in 2019, produces a wide range of cell-based therapies and immunotherapy treatments for cancer and other illnesses. It currently leases a 64,000-square-foot facility at 97 South Street, with plans to add a 112,000-square-foot facility just up the street. The town approved a 14-year tax-increment financing (TIF) agreement with Lykan earlier this year.

Huezo named VP at BankNewport

Hopkinton resident Fredy Huezo was named vice president, business and commercial lending officer at Rhode Island-based BankNewport. He will work with business owners to provide customized solutions that meet their needs and priorities, the bank announced.

Prior to joining BankNewport, Huezo was a vice president, small business banker at Bank of America.